The AACR 2016 meeting presentations differed substantially from previous meetings. The  2016 meeting has brought near certainty that, indeed, defeating cancer is a reachable objective. The road is lengthy, but the speed in analyzing the data and acting upon them towards improvement is unprecedented. You will find the most important information about the AACR cancer meeting in the upcoming Prohost Letter.
In the NEWS
TAPIMMUNE

AstraZeneca (AZN) decided to combine its checkpoint inhibitor durvalumab with an experimental cancer vaccine TPIV . . .